Literature DB >> 18252898

Leptin does not directly regulate the pancreatic hormones amylin and pancreatic polypeptide: interventional studies in humans.

Janice J Hwang1, Jean L Chan, Georgia Ntali, Dalia Malkova, Christos S Mantzoros.   

Abstract

OBJECTIVE: Leptin and the pancreatic hormones amylin and pancreatic polypeptide are being evaluated alone or in combination for the treatment of obesity, but their physiological regulation has not yet been fully elucidated. Thus, we examined whether amylin and pancreatic polypeptide are regulated by caloric intake and/or short- and long-term energy deprivation and whether any potential regulation is mediated by changes in leptin levels. RESEARCH DESIGN AND METHODS: We measured circulating levels of amylin and pancreatic polypeptide after 1) a 75-g glucose load in 28 healthy, normal-weight women, 2) 72-h complete energy deficiency (severe hypoleptinemia) with administration of either placebo or replacement-dose recombinant methionyl human leptin (r-metHuLeptin) in normal-weight men (n = 6) and women (n = 7), and 3) chronic mild energy deficiency (mild hypoleptinemia) in 7 women with hypothalamic amenorrhea before and after r-metHuLeptin administration for 3 months.
RESULTS: Amylin and pancreatic polypeptide levels increased 15 min after a 75-g glucose load and remained elevated at 60 and 120 min (P < 0.0001). Fasting for 72 h decreased leptin (to 21%) and amylin (to 67%) of baseline but not pancreatic polypeptide levels. Normalizing leptin levels with r-metHuLeptin did not alter the fasting-induced decrease in amylin and had no effect on pancreatic polypeptide levels. Neither amylin nor pancreatic polypeptide levels were different in leptin-deficient women with hypothalamic amenorrhea compared with weight-matched control subjects, and normalization of leptin levels with r-metHuLeptin treatment did not alter amylin or pancreatic polypeptide levels.
CONCLUSIONS: Circulating amylin levels increase after a glucose load and decrease in response to short-term complete fasting, but these changes are not mediated by leptin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18252898      PMCID: PMC2753255          DOI: 10.2337/dc07-2433

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  40 in total

1.  Pancreatic polypeptide: a possible role in the regulation of food intake in the mouse. Hypothesis.

Authors:  F Malaisse-Lagae; J L Carpentier; Y C Patel; W J Malaisse; L Orci
Journal:  Experientia       Date:  1977-07-15

2.  Reduced pancreatic polypeptide secretion in obese subjects.

Authors:  J Marco; M A Zulueta; I Correas; M L Villanueva
Journal:  J Clin Endocrinol Metab       Date:  1980-04       Impact factor: 5.958

3.  Interdigestive cycling and post-prandial release of pancreatic polypeptide in severe obesity.

Authors:  O Pieramico; P Malfertheiner; D K Nelson; B Glasbrenner; H Ditschuneit
Journal:  Int J Obes       Date:  1990-12

4.  Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.

Authors:  R E Ratner; R Dickey; M Fineman; D G Maggs; L Shen; S A Strobel; C Weyer; O G Kolterman
Journal:  Diabet Med       Date:  2004-11       Impact factor: 4.359

5.  Distribution and release of human pancreatic polypeptide.

Authors:  T E Adrian; S R Bloom; M G Bryant; J M Polak; P H Heitz; A J Barnes
Journal:  Gut       Date:  1976-12       Impact factor: 23.059

6.  Chronic infusion of the amylin antagonist AC 187 increases feeding in Zucker fa/fa rats but not in lean controls.

Authors:  Valerie Grabler; Thomas A Lutz
Journal:  Physiol Behav       Date:  2004-05

7.  Recombinant human leptin in women with hypothalamic amenorrhea.

Authors:  Corrine K Welt; Jean L Chan; John Bullen; Robyn Murphy; Patricia Smith; Alex M DePaoli; Aspasia Karalis; Christos S Mantzoros
Journal:  N Engl J Med       Date:  2004-09-02       Impact factor: 91.245

8.  Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes.

Authors:  B Ludvik; B Lell; E Hartter; C Schnack; R Prager
Journal:  Diabetes       Date:  1991-12       Impact factor: 9.461

9.  Blunted pancreatic polypeptide responses in children with obesity of Prader-Willi syndrome.

Authors:  W B Zipf; T M O'Dorisio; S Cataland; J Sotos
Journal:  J Clin Endocrinol Metab       Date:  1981-06       Impact factor: 5.958

10.  Low plasma levels of pancreatic polypeptide in obesity.

Authors:  V Lassmann; P Vague; B Vialettes; M C Simon
Journal:  Diabetes       Date:  1980-06       Impact factor: 9.461

View more
  9 in total

Review 1.  The therapeutic potential of metabolic hormones in the treatment of age-related cognitive decline and Alzheimer's disease.

Authors:  John Grizzanti; Hyoung-Gon Lee; Antoni Camins; Merce Pallas; Gemma Casadesus
Journal:  Nutr Res       Date:  2016-11-08       Impact factor: 3.315

Review 2.  Leptin in human physiology and pathophysiology.

Authors:  Christos S Mantzoros; Faidon Magkos; Mary Brinkoetter; Elizabeth Sienkiewicz; Tina A Dardeno; Sang-Yong Kim; Ole-Petter R Hamnvik; Anastasia Koniaris
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-07-26       Impact factor: 4.310

3.  Amylin and leptin activate overlapping signalling pathways in an additive manner in mouse GT1-7 hypothalamic, C₂C₁₂ muscle and AML12 liver cell lines.

Authors:  H-S Moon; J P Chamberland; C S Mantzoros
Journal:  Diabetologia       Date:  2011-10-14       Impact factor: 10.122

4.  Proteasome regulates turnover of toxic human amylin in pancreatic cells.

Authors:  Sanghamitra Singh; Saurabh Trikha; Anjali Sarkar; Aleksandar M Jeremic
Journal:  Biochem J       Date:  2016-06-23       Impact factor: 3.857

5.  Functional proteasome complex is required for turnover of islet amyloid polypeptide in pancreatic β-cells.

Authors:  Diti Chatterjee Bhowmick; Aleksandar Jeremic
Journal:  J Biol Chem       Date:  2018-07-16       Impact factor: 5.157

6.  Circulating fetuin-A levels are not affected by short and long-term energy deprivation and/or by leptin administration.

Authors:  Janice J Hwang; Bindiya Thakkar; John P Chamberland; Christos S Mantzoros
Journal:  Metabolism       Date:  2014-02-17       Impact factor: 8.694

7.  Leptin and amylin act in an additive manner to activate overlapping signaling pathways in peripheral tissues: in vitro and ex vivo studies in humans.

Authors:  Hyun-Seuk Moon; John P Chamberland; Kalliope N Diakopoulos; Christina G Fiorenza; Florencia Ziemke; Benjamin Schneider; Christos S Mantzoros
Journal:  Diabetes Care       Date:  2010-09-24       Impact factor: 19.112

Review 8.  The role of leptin and low testosterone in obesity.

Authors:  Kajal Khodamoradi; Zahra Khosravizadeh; Deepa Seetharam; Suresh Mallepalli; Natoli Farber; Himanshu Arora
Journal:  Int J Impot Res       Date:  2022-01-31       Impact factor: 2.408

Review 9.  Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals.

Authors:  Hyun-Seuk Moon; Maria Dalamaga; Sang-Yong Kim; Stergios A Polyzos; Ole-Petter Hamnvik; Faidon Magkos; Jason Paruthi; Christos S Mantzoros
Journal:  Endocr Rev       Date:  2013-03-08       Impact factor: 19.871

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.